24小时热门版块排行榜    

查看: 519  |  回复: 2

2010020170

金虫 (小有名气)

[交流] 【求助】氯雷他定片 国外标准 已有2人参与

有谁知道 氯雷他定片的国外标准 我不知道在哪可以查到 谢谢
回复此楼
让自己活得精彩
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

主救

金虫 (正式写手)

海阔天空

★ ★ ★
小木虫(金币+0.5):给个红包,谢谢回帖交流
koria0727(金币+2):谢谢提供。 2011-01-15 16:36:11
USP32-NF27收载过。
Loratadine Tablets
» Loratadine Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of loratadine (C22H23ClN2O2).
Packaging and storage— Preserve in tight containers, and store between 2 and 30. Protect from excessive moisture if packaged in blisters.
USP Reference standards 11—
USP Loratadine RS  .
Identification—
A: Thin-Layer Chromatographic Identification Test 201—
Test solution— Transfer an accurately weighed quantity of Tablets, equivalent to about 20 mg of loratadine, to a centrifuge tube. Add 5.0 mL of a mixture of chloroform and methanol (1:1), rotate for 30 minutes, and centrifuge.
Standard solution— Dissolve an accurately weighed quantity of about 20 mg of USP Loratadine RS in 5 mL of a mixture of chloroform and methanol (1:1), and mix.
Application volume: 5 µL.
Developing solvent system: ethyl ether and diethylamine (40:1), in a paper-lined tank.
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Dissolution 711—
Medium: 0.1 N hydrochloric acid; 900 mL.
Apparatus 2: 50 rpm.
Time: 60 minutes.
Procedure— Determine the amount of C22H23ClN2O2 dissolved from UV absorption at the wavelength of maximum absorbance at about 280 nm on filtered portions of the solution under test, suitably diluted with Dissolution Medium, if necessary, in comparison with a Standard solution having a known concentration of USP Loratadine RS in the same Medium.
Tolerances— Not less than 80% (Q) of the labeled amount of C22H23ClN2O2 is dissolved in 60 minutes.
Uniformity of dosage units 905: meet the requirements.
Related compounds—
0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, and Diluent— Proceed as directed in the Assay under Loratadine.
Standard stock solution— Prepare as directed for Standard preparation in the Assay under Loratadine.
Standard solution— Pipet 5.0 mL of the Standard stock solution into a 100-mL volumetric flask, and dilute with Diluent to volume. Dilute quantitatively, and stepwise if necessary, with Diluent to obtain a solution having a known concentration of about 0.8 µg per mL.
Test solution— Use the Assay preparation.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L7. The flow rate is about 1 mL per minute. Chromatograph the Test solution, and record the peak areas as directed for Procedure: the relative retention times are about 0.79 for 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl and 1.0 for loratadine. Chromatograph the Standard solution, and record the peak areas of the main peak as directed for Procedure: the relative standard deviation for replicate injections is not more than 4.0%.
Procedure— Separately inject equal volumes (about 50 µL) of the Test solution and the Standard solution into the chromatograph, record the chromatograms, and measure all of the peak area responses in the Test solution and the peak area of the main peak in the Standard solution. Calculate the percentage of each impurity in the portion of Tablets taken by the formula:
2500(C/L)(ri / rS)
in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard solution; L is the labeled quantity, in mg, of loratadine in each Tablet taken; ri is the peak area response for each impurity in the Test solution; and rS is the peak area response of loratadine in the Standard solution: not more than 0.2% of 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl is found; not more than 0.1% of any other individual impurity is found; and the sum of all impurities, other than 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl, is not more than 0.1%.
Assay—
0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, Diluent, and Standard preparation— Proceed as directed in the Assay under Loratadine.
Assay preparation— Transfer 10 Tablets into a 250-mL volumetric flask, add 100 mL of 0.05 N Hydrochloric acid, and shake for 40 minutes or until the Tablets are completely disintegrated. Add 75 mL of a mixture of methanol and acetonitrile (1:1), and mix. Add 20 mL of 0.6 M Dibasic potassium phosphate, and mix for 5 minutes. Dilute with a mixture of methanol and acetonitrile (1:1) to volume, and mix.
Chromatographic system (see Chromatography 621)— Prepare as directed in the Assay under Loratadine. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k¢, is not less than 3.5; the tailing factor is not more than 1.7; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 15 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak response for the major peaks. Calculate the quantity, in mg, of loratadine (C22H23ClN2O2) in the portion of Tablets taken by the formula:
250C(rU / rS)
in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Daniel K. Bempong, Ph.D.
Senior Scientist
1-301-816-8143 (MDPS05) Monograph Development-Pulmonary and Steroids
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org  
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
1-301-816-8106 (BPC05) Biopharmaceutics05

USP32–NF27 Page 2808
Pharmacopeial Forum: Volume No. 29(4) Page 1045
Chromatographic Column—
LORATADINE TABLETS
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.
海阔天空
2楼2011-01-15 16:16:03
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

2010020170

金虫 (小有名气)

非常感谢
让自己活得精彩
3楼2011-01-16 13:04:49
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 2010020170 的主题更新
普通表情 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 面上项目filecode邪修 +5 西山十月 2026-08-09 7/350 2026-08-10 07:32 by 仁砚薪传
[基金申请] 应该是93bebmhtak前后十一个字符比较关键 +7 Lanmanbaby 2026-08-09 14/700 2026-08-09 23:33 by Tide man
[基金申请] 关于代码变化问题,想知道的进来 +15 且听虎啸 2026-08-07 22/1100 2026-08-09 22:13 by 布布和一二
[基金申请] 这样的filecode谁见过 +10 布布和一二 2026-08-08 21/1050 2026-08-09 17:21 by 天神眷顾
[基金申请] fileCode有新解读? +10 Tide man 2026-08-08 18/900 2026-08-09 12:55 by 仁砚薪传
[基金申请] 关于filecode,很负责任的告诉大家 +6 爱看书的可乐 2026-08-08 7/350 2026-08-08 22:13 by a_niu
[基金申请] 关于豆爷回答的JTJC与%2F数量 +5 yang182083 2026-08-06 7/350 2026-08-08 18:29 by zhanghaozhu
[基金申请] 国基金的申报应该改成非等额制,评价高的钱多评价低的钱少,但是增加资助率 +7 a089 2026-08-07 7/350 2026-08-08 18:05 by gltch
[基金申请] 好奇怪的filecode +3 布布和一二 2026-08-08 4/200 2026-08-08 17:46 by zhanghaozhu
[基金申请] 基金中了 +14 laoda193707 2026-08-06 14/700 2026-08-08 00:23 by 实验小白ha
[基金申请] 关于filecode +4 布布和一二 2026-08-07 7/350 2026-08-07 22:55 by zhanghaozhu
[基金申请] 化学口download_prp&fileCode的固定段好像这几天一直没变,有变的大神么? +3 Tide man 2026-08-07 4/200 2026-08-07 22:39 by Tide man
[基金申请] 固定端突然变了,今天 +6 archvillain 2026-08-06 10/500 2026-08-07 16:03 by 医学老男孩
[基金申请] 大家散了吧,后缀研究没有意义,别浪费时间了,过好目前的每一天,不要焦虑 +5 Tide man 2026-08-06 7/350 2026-08-07 13:11 by 医学老男孩
[基金申请] filecode +14 等待解的谜 2026-08-06 19/950 2026-08-07 12:20 by wlwhappy
[基金申请] 求各位大神看下 100+6 hpkpkpkp 2026-08-05 33/1650 2026-08-06 14:49 by zhiyanjiang
[基金申请] 8月时间戳变的,举个手。玩一下,释放压力 +9 archvillain 2026-08-04 11/550 2026-08-05 20:06 by wlwhappy
[基金申请] 有没有H口的?有收到消息的吗? +3 超级海虾 2026-08-04 3/150 2026-08-04 17:26 by 学教育滴
[基金申请] 纯娱乐,不喜欢勿喷 +7 Tide man 2026-08-04 10/500 2026-08-04 15:10 by loufangrui
[基金申请] 什么时候能放榜呀? +3 Jacob678 2026-08-03 3/150 2026-08-03 16:14 by gltch
信息提示
请填处理意见